Technologies for making new vaccines

Vaccines

Volumn , Issue , 2008, Pages 1335-1355

  Ellis, Ronald W ^a  

^a Israel)   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 85158937058     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-1-4160-3611-1.50064-7     Document Type: Chapter

References (170)

1. AB Sabin and LR Boulger (1973) History of Sabin attenuated poliovirus vaccine. J Biol Stand 1 115-118.
2. JF Enders, SL Katz, MV Milovanovic and A Holloway (1960) Studies on an attenuated measles-virus vaccine I. Development and preparation of the vaccine: Technics for assay of effects of vaccination. N Engl J Med 263 153-159.
3. EB Buynak and MR Hilleman (1966) Live attenuated mumps virus vaccine. I. Vaccine development. Proc Soc Exp Biol Med 123 768-775.
4. M Takahashi, Y Okuno, T Otsuka, et al. (1975) Development of a live attenuated varicella vaccine. Biken J 18 25-33.
5. H Shinefeld, S Black, L Digilio, et al. (2005) Evaluation of a quadrivalent measles, mumps, rubella and varicella vaccine in healthy children. Ped Infect Dis J 24 665-669.
6. E Miller, M Goldacre, S Pugh, et al. (1993) Risk of aseptic meningitis after measles, mumps, and rubella vaccine in UK children. Lancet 341 879-882.
7. DA Henderson (1977) Smallpox eradication. Proc R Soc Lond 199 83-97.
8. AW Artenstein, C Johnson, TC Marbury, et al. (2005) A novel, cell culture-derived smallpox vaccine in vaccinia-naïve adults. Vaccine 23 3301-3309.
9. T Vesikari, AZ Kapikian, A Delem and G Zissis (1986) A comparative trial of Rhesus monkey (RRV-1) and bovine (RIT 4237) oral rotavirus vaccines in young children. J Infect Dis 153 832-839.
10. MB Rennels, RI Glass, PH Dennehy, et al. (1996) Safety and efficacy of high-dose Rhesus-human reassortant rotavirus vaccines-Report of the national multicenter trial. Pediatrics 97 7-13.
11. HF Clark, PA Offit, RW Ellis, et al. (1996) The development of multivalent bovine rotavirus (strain WC3) reassortant vaccine for infants. J Infect Dis 174 S73-S80.
12. HF Maassab and DC DeBorde (1985) Development and characterization of cold-adapted viruses for use as live virus vaccines. Vaccine 3 355-371.
13. SA Plotkin, JD Farquhar, M Katz and F Buser (1969) Attenuation of RA27/3 rubella virus in WI-38 human diploid cells. Am J Dis Child 118 178-185.
14. WEP Beyer, AM Palache, JC de Jong and ADME Osterhaus (2002) Cold-adapted live influenza vaccine versus inactivated vaccine: systemic vaccine reactions, local and systemic antibody response, and vaccine efficacy—A meta-analysis. Vaccine 20 1340-1353.
15. YZ Ghendon, AI Klimov, GI Alexandrova and FI Polezhaev (1981) Analysis of genome composition and reactogenicity of recombinants of cold-adapted and virulent virus strains. J Gen Virol 53 215-224.
16. E McKay, P Higgins, D Tyrrell and C Pringle (1988) Immunogenicity and pathogenicity of temperature-sensitive modified respiratory syncytial virus in adult volunteers. J Med Virol 25 411-421.
17. B Meignier, R Longnecker and B Roizman (1988) In vivo behavior of genetically engineered herpes simplex viruses R7017 and R7020: Construction and evaluation in rodents. J Infect Dis 158 602-614.
18. CS McLean, N Challanain, I Duncan, et al. (1996) Induction of a protective immune response by mucosal vaccination with a DISC HSV-1 vaccine. Vaccine 14 987-992.
19. S Pincus, J Tartaglia and E Paoletti (1995) Poxvirus-based vectors as vaccine candidates. Biologicals 23 159-164.
20. B Moss (1992) Vaccinia virus vectors. R Ellis (Eds) Vaccines: New Approaches to Immunological Problems New York: Marcel Dekker 345-357.
21. MA Perales, DH Schwartz, JA Fabry and J Lieberman (1995) A vaccinia-gp160-based vaccine but not a gp160 vaccine elicits anti-gp160 cytotoxic T lymphocytes in some HIV-1 seronegative vaccinees. J AIDS Hum Retrovir 10 27-35.
22. MS Lee, JM Roos, LC McGuigan, et al. (1992) Molecular attenuation of vaccinia virus: Mutant generation and animal characterization. J Virol 66 2617-2630.
23. J Tartaglia, ME Perkus, J Taylor, et al. (1992) NYVAC: A highly attenuated strain of vaccinia virus. Virology 188 217-232.
24. JL Marshall, JL Gulley, PM Arlen, et al. (2004) Phase 1 study of sequential vaccinations with fowlpox-CEA(6D)—TRICOM, with and without Granulocyte-Macrophage Colony-Stimulating Factor, in patients with Carcinoembryonic Antigen-expressing carcinomas. J Clin Oncology 23 1-12.
25. FL Graham and L Prevec (1992) Adenovirus-based expression vectors and recombinant vaccines. R Ellis (Eds) Vaccines: New Approaches to Immunological Problems New York: Marcel Dekker 363-390.
26. S Schlesinger (1993) Alphaviruses-vectors for the expression of heterologous genes. Trends Biotechnol 11 18-22.
27. SM Jones, H Feldmann, U Ströher, et al. (2005) Live attenuated recombinant vaccine protects nonhuman primates against Ebola and Marburg viruses. Nature Med 11 786-790.
28. M Gabler, S Scheiblhofer, K Kern, et al. (2006) Immunization with a low-dose replicon DNA vaccine encoding ph1 p5 effectively prevents allergic sensitization. J Allergy Clin Immunol 118 734-741.
29. BR Bloom and PEM Fine (1994) The BCG experience: implications for future vaccines against tuberculosis. BR Bloom (Eds) Tuberculosis: Pathogenesis, Prevention and Control Washington DC: ASM Press 531-558.
30. AB Alexandroff, AM Jackson, MA O'Donnell and K James (1999) BCG immunotherapy of bladder cancer: 20 years on. Lancet 353 1689-1694.
31. R Germanier and E Furer (1975) Isolation and characterization of galE mutant Ty21a of Salmonella typhi: A candidate strain for a live, oral typhoid vaccine. J Infect Dis 131 553-558.
32. MM Levine, RE Black, C Ferreccio and R Germanier (1987) Clinical Typhoid Committee. Large-scale field trial of Ty21a live oral typhoid vaccine in enteric-coated capsule formulation. Lancet 2 1049-1052.
33. CO Tacket, G Losonsky, JP Nataro, et al. (1992) Onset and duration of protective immunity in challenged volunteers after vaccination with live oral cholera vaccine CVD 103-HgR. J Infect Dis 166 837-841.
34. KL Kotloff, DN Taylor, MB Sztein, et al. (2002) Phase 1 evaluation of Δ virG Shigella sonnei live, attenuated, oral vaccine strain WRSS1 in healthy adults. Infect Immun 70 2016-2021.
35. C Gonzalez, D Hone, FR Noriega, et al. (1994) Salmonella typhi vaccine strain CVD 908 expressing the circumsporozoite protein of Plasmodium falciparum: Strain construction and safety and immunogenicity in humans. J Infect Dis 169 927-931.
36. JR Butterton, DT Beattie, CL Gardel, et al. (1995) Heterologous antigen expression in Vibrio cholerae vector strains. Infect Immunol 63 2689-2696.
37. FR Noriega, G Losonsky, JY Wang, et al. (1996) Further characterization of DaroA DvirG Shigella flexneri as a mucosal Shigella vaccine and a live-vector vaccine for delivering antigens of enterotoxigenic Escherichia coli. Infect Immunol 64 23-27.
38. PL Goosens, C Montixi, M-F Saron, et al. (1995) Listeria monocytogenes: A live vector able to deliver heterologous proteins within the cytosol and to drive a CD8-dependent T-cell response. Biologicals 23 135-143.
39. CK Stover, VF de la Cruz, TR Fuerst, et al. (1991) New use of BCG for recombinant vaccines. Nature 351 456-460.
40. M Lagranderie, A Murray, B Gicquel, et al. (1993) Oral immunization with recombinant BCG induces cellular and humoral immune responses against the foreign antigen. Vaccine 11 1283-1290.
41. VA Fischetti, D Medaglini and G Pozzi (1996) Gram-positive bacteria for mucosal vaccine delivery. Current Opinion Biotechnol 7 659-666.
42. JM Timmerman and R Levy (1999) Dendritic cell vaccines for cancer immunotherapy. Ann Rev Med 507-529.
43. Small EJ, Fratesi P, Reese DM, et al. Immunotherapy of hormone-refractory prostate cancer with antigen-loaded dendritic cells. J Clin Oncology 18:3894–3903.
44. LM Liau, RM Prins, SM Kiertscher, et al. (2005) Dendritic cell vaccination in glioblastoma patients induces systemic and intracranial T-cell responses modulated by the local central nervous system tumor microenvironment. Clin Cancer Res 11 5515-5525.
45. H Link, Y-M Huang, T Masterman and B-G Xiao (2001) Vaccination with autologous dendritic cells: from experimental autoimmune encephalitis to multiple sclerosis. J Neuroimmunol 114 1-7.
46. WA Werzberger, B Mensch, B Kuter, et al. (1992) A controlled trial of a formalin-inactivated hepatitis A vaccine in healthy children. New Engl J Med 327 453-457.
47. JD Cherry, PA Brunell, GS Golden and DT Karzon (1988) Report of the task force on pertussis and pertussis immunization-1988. Pediatrics 81 939.
48. JD Clemens, DA Sack, JR Harris, et al. (1990) Field trial of oral cholera vaccines in Bangladesh: Results from three-year follow-up. Lancet 355 270-273.
49. A-M Svennerholm, J Holmgren and DA Sack (1989) Development of oral vaccines against enterotoxigenic Escherichia coli diarrhoea. Vaccine 7 196-198. UPDATE
50. AD Murdin, L Barreto and S Plotkin (1996) Inactivated polio vaccines: past and present experience. Vaccine 14 735-746.
51. CR Crawford, AM Faiza, FA Mukhlis, et al. (1984) Use of zwitterionic detergent for the preparation of an influenza virus vaccine. 1. Preparation and characterization of disrupted virions. Vaccine 2 193-198.
52. SA Plotkin (1980) Rabies vaccine prepared in human cell cultures: Progress and perspectives. Rev Infect Dis 2 433-447.
53. CH Hoke, A Nisalak and N Sangawhipa (1988) Protection against Japanese encephalitis by inactivated vaccines. N Engl J Med 319 608-614.
54. PJ Provost, JV Hughes, WJ Miller, et al. (1986) An inactivated hepatitis A viral vaccine of cell culture origin. J Med Virol 19 23-31.
55. MS Mitchell (1998) Perspective on allogeneic melanoma lysates in active specific immunotherapy. Semin Oncol 25 623-635.
56. D Berd (2004) M-Vax: an Autologous, hapten-modified vaccine for human cancer. Expert Rev Vaccines 3 521-527.
57. M Kusumoto, S Umeda, A Ikubo, et al. (2001) Phase 1 clinical trial of irradiated autologous melanoma cells adenovirally transduced with human GM-CSF gene. Cancer Immunol Immunother 50 373-381.
58. S Trudel, C Li Dodgson, et al. (2001) Adenovirus engineered interleukin-2 autologous plasma cell vaccination after high-dose chemotherapy for multiple myeloma—a phase 1 study. Leukemia 15 846-854.
59. QL Choo, G Kuo, AJ Weiner, et al. (1989) Isolation of a cDNA clone from a blood-borne non-A, non-B viral hepatitis genome. Science 244 359-362.
60. M Pizza, V Scarlato, V Masignani, et al. (2000) Identification of vaccine candidates against serogroup B meningococcus by whole-genome sequencing. Science 287 1816-1820.
61. P Moingeon (2001) Cancer vaccines. Vaccine 19 1305-1326.
62. MR Hilleman, AU Bertland, EB Buynak, et al. (1978) Clinical and laboratory studies of HBsAg vaccine. GN Vyas, SN Cohen, R Schmid (Eds) Viral Hepatitis Philadelphia: Franklin Institute Press 525-541.
63. D Greco, S Salmaso, P Mastrantonio, et al. (1996) A controlled trial of two acellular vaccines and one whole-cell vaccine against pertussis. New Engl J Med 334 341-348.
64. L Gustafson, HO Hallander, P Olin, et al. (1996) A controlled trial of a two-component acellular, a five-component acellular, and a whole-cell pertussis vaccine. New Engl J Med 334 349-355.
65. H-J Schmitt, K. Wirsingvon König, A Neiss, et al. (1996) Efficacy of acellular pertussis vaccine in early childhood after household exposure. J Am Med Assoc 275 37-41.
66. S Janetski, V Rosenhauer, H Lochs, et al. (2000) Immunization of cancer patients with autologous cancer-derived heat-shock protein gp96 preparations: a pilot study. Int J Cancer 88 232-238.
67. FG Jones and JM Moss (1936) Studies on tetanus toxoid. I. The antitoxic titer of human subject following immunization with tetanus toxoid and tetanus alum precipitated toxoid. J Immunol 30 115-125.
68. G Ramon (1923) Sur le pouvoir floculant et sur les proprietes immunisantes d'une toxin diphterique rendue anatoxique (anatoxine). Compt Rend Acad Sci 177 1338-1340.
69. M Chazono, I Yoshida and T Konobe (1988) The purification and characterization of an acellular pertussis vaccine. J Biol Stand 16 83-89.
70. L Nencioni, MG Pizza, M Bugnoli, et al. (1990) Characterization of genetically inactivated pertussis toxin mutants: Candidates for a new vaccine against whooping cough. Infect Immunol 58 1308-1315.
71. G Giannini, R Rappuoli and G Ratti (1984) The amino-acid sequence of two non-toxic mutants of diphtheria toxin: CRM 45 and CRM 197. Nucleic Acids Res 12 4063-4069.
72. P Valenzuela, A Medina, WJ Rutter, et al. (1982) Synthesis and assembly of hepatitis-B virus surface-antigen particles in yeast. Nature 298 347-350.
73. Y Thanavala, Y-F Yang, P Lyons, et al. (1995) Immunogenicity of transgenic plant-derived hepatitis B surface antigen. Proc Natl Acad Sci USA 92 3358-3361.
74. LL Villa, RLR Costa, CA Petto, et al. (2005) Prophylactic quadrivalent human papillomavirus (types 6, 11, 16 and 18) L1 virus-like particle vaccine in young women; a randomized double blind placebo-controlled multicenter Phase II efficacy trial. Lancet Oncology 6 271-278.
75. C Van Hoecke, M Comberbach, D De Grave, et al. (1996) Evaluation of the safety, reactogenicity and immunogenicity of three recombinant outer surface protein (OspA) Lyme vaccines in healthy adults. Vaccine 14 1620-1626.
76. PW Berman, TJ Gregory, L Riddle, et al. (1990) Protection of chimpanzees from infection by HIV-1 after vaccination with recombinant glycoprotein gp120 but not gp160. Nature 345 622-625.
77. AGM Langenburg, RL Burke, SF Adair, et al. (1995) A recombinant glycoprotein vaccine for herpes simplex type 2: Safety and efficacy. Ann Intern Med 122 889-898.
78. Hamel J, Charland N, Pineau I, et al. Prevention of pneumococcal disease in mice immunized with conserved surface-accessible proteins. Infect Immun 72:2659–2670.
79. SA McNeil, SA Halperin, JM Langley, et al. (2005) Safety and immunogenicity of 26-valent Group A Streptococcus vaccine in healthy adult volunteers. Clin Infect Dis 41 1114-1122.
80. T Takai, T Yokota, M Yasue, et al. (1997) Engineering of the major house mite allergen Der f2 for allergen-specific immunotherapy. Nature Biotechnol 15 754-760.
81. RJ Keller, GS Eisenbarth and RA Jackson (1993) Insulin prophylaxis of individuals at risk of type-1 diabetes. Lancet 341 927-928.
82. LC Harrison (2001) Risk assessment, prediction and prevention of type 1 diabetes. Pediatric Diabetes 2 71-82.
83. NR Chu, HB Wu, T-C Wu, et al. (2000) Immunotherapy of human papillomavirus (HPV) type 16 E7-expressing tumour by administration of fusion protein comprising Mycobacterium bovis bacille Calmette-Guérin (BCG) hsp65 and HPV 16 E7. Clin Exp Immunol 121 216-225.
84. CP Locher, TM Paidhunga, RG Whalen and J Punnoyen (2005) DNA shuffling and screening strategies for vaccine efficacy. DNA Cell Biol 24 256-263.
85. F Zavala, AH Cochrane, EH Nardin, et al. (1983) Circumsporozoite proteins of malaria parasites contain a single immunodominant region with two or more identical epitopes. J Exp Med 157 1947-1957.
86. D Schenk, R Barbour, W Dunn, et al. (1999) Immunization with amyloid-b attenuates Alzheimer-disease-like pathology in the PDAPP mouse. Nature 400 173-177.
87. KA Bojang, F Olodude, M Pinder, et al. (2005) Safety and immunogenicity of RTS, S/AS02A candidate malaria vaccine in Gambian children. Vaccine 23 4148-4157.
88. F Schödel, D Peterson, J Hughes, et al. (1996) Hybrid hepatitis B virus core antigen as a vaccine carrier moiety. I. Presentation of foreign epitopes. J Biotechnol 44 91-96.
89. MH Davidson, K Maki, D Umporowicz, et al. (2003) The safety and immunogenicity of a CETP vaccine in healthy adults. Artherosclerosis 169 113-120.
90. DA Herrington, DF Clyde, G Losonsky, et al. (1987) Safety and immunogenicity in man of a synthetic peptide in malaria vaccine against Plasmodium falciparum sporozoites. Nature 328 257-259.
91. H Nash, GP Talwar, SJ Segal, et al. (1980) Observations on the antigenicity and clinical effects of a candidate anti-pregnancy vaccine: Beta-subunit of human chorionic gonadotropin linked to tetanus toxoid. Fertil Steril 34 328-335.
92. GP Talwar (1997) Fertility regulating and immunotherapeutic vaccines reaching human trials stage. Hum Reprod Update 3 301-310.
93. S Zhang, LA Graeber, F Helling, et al. (1996) Augmenting the immunogenicity of synthetic MUC1 peptide vaccine in mice. Cancer Res 56 3315-3319.
94. T Fehr, MF Bachmann, E Bucher, et al. (1997) Role of repetitive antigen patterns for induction of antibodies against antibodies. J Exp Med 185 1785-1792.
95. JP Tam, P Clavijo, Y-A Lu, et al. (1990) Incorporation of T and B epitopes of the circumsporozoite protein in a chemically defined synthetic vaccine against malaria. J Exp Med 171 299-306.
96. A Meola, P Delmastro, P Monaci, et al. (1995) Derivation of vaccines from mimetopes: Immunologic properties of human hepatitis B surface antigen mimetopes displayed on filamentous phage. J Immunol 154 3162-3172.
97. T Kieber-Emmons, P Luo, J Qiu, et al. (1999) Vaccination with carbohydrate peptide mimotopes promotes anti-tumor responses. Nature Biotech 17 660-665.
98. M Agadjanyan, P Luo, J Westerink, et al. (1997) Peptide mimicry of carbohydrate epitopes on human immunodeficiency virus. Nature Biotech 15 547-551.
99. A Vitiello, G Ishioka, HM Grey, et al. (1997) Development of a lipopeptide-based therapeutic vaccine to treat chronic hepatitis B infection. I. Induction of a primary cytotoxic T-lymphocyte response in humans. J Clin Inv 95 341-349.
100. P Daftarian, R Sharan, W Haq, et al. (2005) Novel conjugates of epitope fusion peptides with CpG-ODN display enhanced immunogenicity and HIV recognition. Vaccine 23 3453-3468.
101. IR Cohen (2000) T-cell vaccination for autoimmune disease: a panorama. Vaccine 20 706-710.
102. Y Ge, RI Grossman, JK Udupa, et al. (2000) Glatiramer acetate (Copaxone) treatment in relapsing-remitting MS: quantitative MR assessment. Neurology 54 813-817.
103. LP Rodrigues, R Schneerson and JB Robbins (1971) Immunity to H. influenzae type b I. The isolation, and some physicochemical, serologic and biologic properties of the capsular polysaccharide of H. influenzae type b. J Immunol 107 1071-1080.
104. EC Gotschlich, TY Liu and MS Artenstein (1969) Human immunity to the meningococcus. III. Preparation and immunochemical properties of the group A, group B and group C meningococcal polysaccharides. J Exp Med 129 1349-1365.
105. EG Kass (1981) Assessment of the pneumococcal polysaccharide vaccine. Rev Infect Dis 3 S1-S197.
106. PJ Kniskern, S Marburg and RW Ellis (1995) Haemophilus influenzae type b Conjugate Vaccines. M Powell, M M. Newman (Eds) Vaccine Design: The Subunit Approach New York: Plenum 673-694.
107. S Black, H Shinefield, B Fireman, et al. (2000) Efficacy, safety and immunogenicity of heptavalent pneumococcal conjugate vaccine in children. Pediatr Infect Dis J 19 187-195.
108. T Wuorimaa, H Kayhty, O Leroy and J Eskola (2001) Tolerability and immunogenicity of an 11-valent pneumococcal conjugate vaccine in adults. Vaccine 19 1863-1869.
109. MR Wessels, LC Paoletti, DL Kasper, et al. (1990) Immunogenicity in animals of a polysaccharide-protein conjugate vaccine against type III group B I. J Clin Invest 86 1428-1433.
110. BM Sandmaier, DV Oparin, LA Holmberg, et al. (1999) Evidence of a cellular immune response against Sialyl-Tn in breast and ovarian cancer patients after high-dose chemotherapy, stem cell rescue, and immunization with Theratope STn-KLH cancer vaccine. J Immunotherapy 22 54-66.
111. PB Chapman, DM Morrissey, KS Panageas, et al. (2000) Induction of antibodies against GM2 ganglioside by immunizing melanoma patients using GM2-keyhole limpet hemocyanin + QS21 vaccine: A dose-response study. Clin Cancer Res 6 874-879.
112. RC Kennedy, K Adler-Storthz, RD Henkel, et al. (1983) Immune response to hepatitis B surface antigen: Enhancement by prior injection of antibodies to the idiotype. Science 221 853-855.
113. D Herlyn, M Wettendorff, D Iliopoulos, et al. (1989) Modulation of cancer patients’ immune responses by administration of anti-idiotypic antibodies. Viral Immunol 2 271-276.
114. DE Reece, KA Foon, M Bhattacharya-Chatterjee, et al. (2000) Use of the anti-idiotype antibody vaccine TriAb after autologous stem cell transplantation in patients with metastatic breast cancer. Bone Marrow Transplantation 26 729-735.
115. JM Grzych, M Capron, PH Lambert, et al. (1985) An anti-idiotype vaccine against experimental schistosomiasis. Nature 316 74-76.
116. BA Martell, E Mitchell, J Poling, et al. (2005) Vaccine pharmacotherapy for the treatment of cocaine dependence. Biol Psych 58 158-164.
117. JA Wolff, RW Malone, P Williams, et al. (1990) Direct gene transfer into mouse muscle in vivo. Science 247 1465-1468.
118. JB Ulmer, JC Sadoff and MA Liu (1996) DNA vaccines. Current Opinion Immunol 8 531-536.
119. LK Roberts, LJ Barr, DH Fuller, et al. (2005) Clinical safety and efficacy of a powdered hepatitis B nucleic acid vaccine delivered to the epidermis by a commercial prototype device. Vaccine 23 4867-4878.
120. J-S Remy, C Sirlin, P Vierling and J-P Behr (1994) Gene transfer with a series of lipophilic DNA-binding molecules. Bioconjugate Chem 5 647-654.
121. L Coney, B Wang, KE Ugen, et al. (1994) Facilitated DNA inoculation induces anti-HIV-1 immunity in vivo. Vaccine 12 1545-1550.
122. AM Krieg, A-K Yi, S Matson, et al. (1995) CpG motifs in bacterial DNA trigger direct B-cell activation. Nature 374 546-549.
123. JA Thompson, R Figlin, E Galanis, et al. (2000) Phase II trial of plasmid DNA/lipid (leuvectin) immunotherapy in patients with metastatic renal cell carcinoma. Clin Cancer Res 6 517.
124. TW Dubensky, DA Driver, JM Polo, et al. (1996) Sindbis virus DNA-based expression vectors: Utility for in vitro and in vivo gene transfer. J Virol 70 508-519.
125. H Ying, TZ Zaks, R-F Wang, et al. (1999) Cancer therapy using a self-replicating RNA vaccine. Nature Medicine 5 823-827.
126. RM Kofler, JH Aberle, SW Aberle, et al. (2004) Mimicking live flavivirus immunization with a noninfectious RNA vaccine. Proc Nat Acad Sci USA 101 1951-1956.
127. SJ Kent, V Stallard, L Corey, et al. (1994) Analysis of cytotoxic T-lymphocyte responses to SIV proteins in SIV-infected macaques using antigen-specific stimulation with recombinant vaccinia and fowlpox viruses. AIDS Res Hum Retrovir 10 551-560.
128. LF Fries, J Tartaglia, J Taylor, et al. (1996) Human safety and immunogenicity of a canarypox-rabies glycoprotein recombinant vaccine: an alternative poxvirus vector system. Vaccine 14 428-434.
129. DR Sizemore, AA Branstrom and JC Sadoff (1996) Attenuated Shigella as a DNA delivery vehicle for DNA-mediated immunization. Science 270 299-302.
130. FR Vogel and MF Powell (1996) A compendium of vaccine adjuvants and excipients. MF Powell, MJ Newman (Eds) Vaccine Design. The Subunit and Adjuvant Approach New York: Plenum 141-228.
131. JC Cox and AR Coulter (1997) Adjuvants-a classification and review of modes of action. Vaccine 15 248-256.
132. S Shirodkar, RL Hutchinson, JL White and SL Hem (1990) Aluminum compounds used as adjuvants in vaccines. Pharm Res 7 1282-1288.
133. S De Donato, D Granoff, M Minutello, et al. (1999) Safety and immunogenicity of MF59-adjuvanted influenza vaccine in the elderly. Vaccine 17 3094-3101.
134. G Boland, J Beran, M Lievens, et al. (2004) Safety and immunogenicity profile of an experimental hepatitis B vaccine adjuvanted with AS04. Vaccine 23 316-320.
135. AM Krieg (2003) CpG motifs: the active ingredient in bacterial extracts? Nature Med 9 831-835.
136. CD Elson and W Falding (1984) Generalized systemic and mucosal immunity in mice after mucosal stimulation with cholera toxin. J Immunol 132 2736-2744.
137. U Gluck, J-O Gebbers and R Gluck (1999) Phase 1 evaluation of intranasal virosomal influenza vaccine with and without Escherichia coli heat-labile toxin in adult volunteers. J Virology 73 7780-7786.
138. G Douce, C Turcottee, I Cropley, et al. (1995) Mutants of Escherichia coli heat-labile toxin lacking ADP-ribosylating activity acts as non-toxic mucosal adjuvants. Proc Natl Acad Sci USA 92 1644-1648.
139. LC Agren, L Ekman, B Lowenadler and N Lycke (1997) A genetically-engineered nontoxic vaccine adjuvant that combines B-cell targeting with immunomodulation by cholera toxin A1 subunit. J Immunol 158 3936-3946.
140. S North and C Butts (2005) Vaccination with BLP25 liposome vaccine to treat non-small cell lung and prostate cancers. Expert Rev Vacc 4 249-257.
141. Y Wu, X Wang and KL Csencsits (2001) M cell-targeted DNA vaccination. Proc Nat Acad Sci USA 98 9318-9323.
142. E Medina, SR Talay, GS Chhatwal and CA Guzman (1998) Fibronectin-binding protein 1 of Streptococcus pyogenes is a promising adjuvant for antigens delivered by mucosal route. Eur J Immunol 28 1069-1077.
143. GM Glenn, T Scharton-Kersten, Vassell, et al. (1999) Transcutaneous immunization using bacterial ADP-ribosylating exotoxins as antigens and adjuvants. Infect Immun 67 1100-1106.
144. JD Clemens, DA Sack, JR Harris, et al. (1988) Impact of B subunit killed whole-cell and killed whole-cell-only oral vaccines against cholera upon treated diarrhoeal illness and mortality in an area endemic for cholera. Lancet 1 1375-1379.
145. G Pialoux, J-L Excler, Y Riviere, et al. (1995) A prime-boost approach to HIV preventive vaccine using recombinant canarypox virus expressing glycoprotein 160 (MN) followed by recombinant glycoprotein 160 (MN/LAI). AIDS Res Hum Retroviruses 11 373-381.
146. D Salmon-Ceron, J-L Excler, D Sicard, et al. (1995) Safety and immunogenicity of a recombinant HIV type 1 glycoprotein 160 boosted by a V3 synthetic peptide in HIV-negative volunteers. AIDS Res Hum Retroviruses 11 1479-1486.
147. MD Lubeck, R Ntuk, M Myagkikh, et al. (1997) Long-term protection of chimpanzees against high-dose HIV-1 challenge induced by immunization. Nature Med 3 651-658.
148. RW Ellis (Ed.) (1999) Combination Vaccines Totawa, New Jersey: Humana
149. RJ Gerety, LA Smallwood and E Tabor (1980) Hepatitis B immune globulin and immune serum globulin. N Engl J Med 303 529-532.
150. JA Zaia, MJ Levine, GG Wright and GF Grady (1978) A practical method for preparation of varicella-zoster immunoglobulin. J Infect Dis 137 601-608.
151. DR Snydman, BG Werner, B Heinze-Lacey, et al. (1987) Use of cytomegalovirus immune globulin to prevent cytomegalovirus disease in renal-transplant recipients. N Engl J Med 317 1049-1054.
152. JP DeVincenzo, RL Hirsch, RJ Fuentes and FH Top Jr (2000) Respiratory syncytial virus immune globulin treatment of lower respiratory tract infection in pediatric patients undergoing bone marrow transplantation—a compassionate use experience. Bone Marrow Transpl 25 161-165.
153. M Eddleston, S Rajapakse, Rajakanthan, et al. (2000) Anti-digoxin Fab fragments in cardiotoxicity induced by ingestion of yellow oleander: a randomised controlled trial. Lancet 355 967-972.
154. SD Rubbo and JC Suri (1962) Passive immunization against tetanus with human immune globulin. Brit Med J 2 79-81.
155. J Baselga (2001) Clinical trials of Herceptin (trastuzumab). Int J Cancer Supplement 1 S18-S24.
156. AJ Grillo-Lopez, CA White, C Varns, et al. (1999) Overview of the clinical development of Rituximab: first monoclonal antibody approved for the treatment of lymphoma. Sem Oncol 26 66-73.
157. G Kohler and C Milstein (1975) Continuous cultures of fused cells secreting antibody of predefined specificity. Nature 256 495-497.
158. P Holliger and PJ Hudson (2005) Engineered antibody fragments and the rise of single domains. Nature Biotech 23 1126-1136.
159. Noujaim AA, Schultes BC, Baum RP, Madiyalakan R. Induction of CA125-specific B- and T-cell responses in patients injected with MAb-B43.13-Evidence for antibody-mediated antigen processing and presentation of CA125 in vivo. Cancer Biotherapy & Radiopharmaceuticals 16:187–203.
160. Y Matsumoto, T Sugano, C Miyamoto and Y Masuho (1986) Generation of hybridomas producing human monoclonal antibodies against human cytomegalovirus. Biochem Biophys Res Commun 137 273-280.
161. RF Irie, T Matsuki and DL Morton (1999) Human monoclonal antibody to ganglioside GM2 for melanoma treatment. Lancet 1 786-787.
162. MK Gorny, J-Y Xu, V Gianakakos, et al. (1991) Production of site-selected neutralizing human monoclonal antibodies against the third variable domain of the human immunodeficiency virus type 1 envelope glycoprotein. Proc Nat Acad Sci USA 87 3238-3242.
163. JD Marks, HR Hoogenbaum, TP Bonnert, et al. (1991) By-passing immunization. Human antibodies from V-gene libraries displayed on phage. J Mol Biol 222 581-597.
164. R Matthews, S Hodgetts and J Burnie (1995) Preliminary assessment of a human recombinant antibody fragment to hsp90 in murine invasive Candidiasis. J Infect Dis 171 1668-1671.
165. MJ Mendez, LL Green, JRF Corvalan, et al. (1997) Functional transplant of megabase human immunoglobulin loci recapitulates human antibody response in mice. Nat Gen 15 146-156.
166. XD Yang, XC Jia, JR Corvalan, et al. (2001) Development of ABX-EGF, a fully human anti-EGF receptor monoclonal antibody, for cancer therapy. Crit Rev Oncol Hematol 38 17-23.
167. L Riechmann, M Clark, H Waldmann and G Winter (1988) Reshaping human antibodies for therapy. Nature 332 323-327.
168. PR Tempest, P Bremner, M Lambert, et al. (1991) Reshaping a human monoclonal antibody to inhibit human respiratory syncytial virus infection in vivo. Biotechnol 9 266-271.
169. X Saez-Llorens, E Castano, D Null, et al. (1999) Safety and pharmacokinetics of an intramuscular humanized monoclonal antibody to respiratory syncytial virus in premature infants and infants with bronchopulmonary dysplasia. Pediatr Infect Dis J 17 787-791.
170. TB Casale, J Condemi, G Della Cioppa, et al. (2001) Effect of omalizumab on syptoms of seasonal allergic rhinitis: A randomized controlled trial. JAMA 286 2956-2967.